Spots Global Cancer Trial Database for Bioenergetic Profiling and Cognition in GBM Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Bioenergetic Profiling and Cognition in GBM Patients

Official Title: Blood-based Bioenergetic Profiling and Cognition in Glioblastoma Patients

Study ID: NCT03939858

Conditions

Glioblastoma

Interventions

Cognitive Assessment

Blood Collection

Bioenergetic Profiling

Study Description

Brief Summary: This trial studies the use of blood-based bioenergetic profiling and cognitive testing in assessing patients with glioblastoma undergoing chemoradiation therapy. The purpose of this pilot research study is to find out if it is possible to see changes in participants' mitochondria, parts of a cell that produce energy, that might be associated with changes in participants' brain function after chemoradiation therapy.

Detailed Description: Primary Objective: • To determine the feasibility of performing bioenergetic profiling in glioblastoma patients receiving chemoradiation by ascertaining the proportion of patients who have enough white blood cells in a 16 mL blood to successfully perform the profiling assays. Secondary Objectives: • To determine if either pre-radiotherapy bioenergetic profile or the change in bioenergetic profile from pre-radiotherapy to post-radiotherapy are predictive of subacute cognitive decline after radiation. OUTLINE: Patients undergo neurocognitive testing over 1 hour using a customized battery of tests designed for brain tumor patients at Wake Forest Baptist Comprehensive Cancer Center. Patients also undergo blood collection at baseline and at 1 and 3 months post radiotherapy.